Venkat Krishnamurthy

Venkat Krishnamurthy, Ph.D., is senior vice president of platform at Korro Bio, with over ten years of experience in RNA based therapeutics, oligonucleotide chemistry and non-viral delivery technologies.

Before arriving at Korro, Dr. Krishnamurthy held an executive director role at Eli Lilly & Company, where he was responsible for strategic direction for Lilly’s genetic medicine portfolio. Prior to this, Dr. Krishnamurthy was a team lead at AstraZeneca, where he built a new modalities group at the Boston site to support the company’s mRNA and genome editing projects from discovery to clinic. He began his industry career at Dicerna Pharmaceuticals and was one of the early chemists to advance the company’s siRNA platform. He also made critical contributions to the advancement of Nedosiran, Dicerna’s first GalNAc-siRNA program currently in Phase 3. Ahead of his experience in industry, Dr. Krishnamurthy was a faculty member at Harvard Medical School, where he led a lab focused on non-viral delivery for cell therapy and tissue engineering. He has contributed to over 30 publications and patents, and some of his work laid the foundation for projects funded by the National Institutes of Health. Dr. Krishnamurthy earned his doctorate in organic chemistry from the University of Illinois, Chicago, and completed postdoctoral training at Princeton University. He also holds bachelor’s and master’s degrees in chemistry from Loyola College and the Indian Institute of Technology, Chennai, respectively.